What Happens to 7-OH Brands After August 5, 2026?

The DEA's July 2026 filing set a specific threshold for 7-hydroxymitragynine, and the temporary scheduling order may publish on or after August 5, 2026, taking effect the day it publishes. That much is documented. The less documented question — the one retailers and consumers are actually asking — is what the market looks like on the other side of that date.

This post walks through it factually. It covers which product categories sit above the threshold based on their own published specifications, what typically happens to shelf inventory in a transition like this, and how to think about the botanical category more broadly. If you have not yet read the background, start with Is 7-OH Banned? for the timeline and The DEA's 7-OH Threshold Explained for the arithmetic.

The Threshold, in One Paragraph

For kratom plant material, the threshold is 0.05% 7-OH. For synthetically produced or further-processed articles — extracts, concentrates, processed edibles, and pressed pills — the threshold is 0.05% 7-OH or 1 milligram of 7-OH per article, whichever is triggered first. The action is aimed at enhanced, concentrated, synthetic, and semi-synthetic 7-OH, not at ordinary botanical leaf carrying only trace naturally-occurring amounts. The full text is in the Federal Register notice (91 FR 40917, Docket No. DEA-1570) published July 6, 2026.

Where Concentrated Tablet Brands Sit

A number of brands in the current market sell pressed 7-OH tablets and shots, and they label their products with the 7-OH content. Press'd, 7Tabz, and Dozo Perks are among the names consumers will recognize; across the category, published tablet strengths generally run from roughly 18 mg up to 200 mg of 7-OH per unit.

Set those published figures against a 1 milligram per-article threshold and the comparison is straightforward arithmetic. Nothing about it is a matter of interpretation.

To be clear about what this table is and is not: it compares publicly stated product specifications to a publicly stated regulatory number. It is not a statement about the quality, safety, or conduct of any company, and it is not a legal conclusion about any specific product. Companies make their own decisions about reformulation, discontinuation, and compliance, and only a company's own counsel can speak to its position.

The observation is narrower than that: the concentrated-tablet category as a whole is formulated at strengths one to two orders of magnitude above the per-article figure the DEA identified. There is no version of that math that comes out close.

What Consumers Should Expect on the Shelf

Transitions like this tend to follow a recognizable pattern. Based on how regulated-product categories have moved in the past, here is what is reasonable to anticipate:

• Products coming off shelves. Retailers generally act ahead of an effective date rather than on it. Expect concentrated 7-OH products to begin disappearing from smoke shops, convenience stores, and gas stations through late July and early August.
• Inventory clearance. Some retailers will discount existing stock to move it before the date. Consumers may see unusual pricing on 7-OH tablets and shots in the coming weeks.
• Online storefronts changing. Payment processors and platform policies often move faster than the underlying regulation. Some online sellers will delist affected products well before the order publishes.
• Reformulation announcements. Some brands will announce products they describe as reformulated. Whether any given reformulation lands beneath the threshold is a question a certificate of analysis has to answer, not a marketing page.
• Uneven timing by state. States regulate independently of federal scheduling, and several already have their own rules on these compounds. Availability will not shift uniformly across the country.

One practical note for consumers: the per-article prong applies to the unit as sold. If you want to evaluate a specific product, the number to look for is the milligrams of 7-OH in a single tablet, capsule, or shot — not the total in the package, and not the total alkaloid figure.

How Retailers Are Handling the Transition

On the retail side, the work between now and the effective date is mostly documentary. Buyers are pulling certificates of analysis on every SKU that touches the category and checking whether 7-OH is itemized at all — many panels report only mitragynine or total alkaloids, which cannot answer the threshold question. Where 7-OH is reported as a percentage, buyers are converting to milligrams per unit, since 0.05% works out to 0.5 mg per gram of material.

Shops that carry a broad botanical assortment are also rebalancing. Categories with no relationship to kratom at all — adaptogenic and traditional botanicals sold as dietary supplements — are getting more shelf space as the concentrated 7-OH category contracts. The Congressional Research Service's legal sidebar on the scheduling mechanism is a useful reference for anyone trying to understand how long the temporary placement runs and what comes after it.

A Note on Kratom-Free Botanical Alternatives

This closing section describes our own product category. It is included for readers who have asked what else exists in the botanical space.

Many consumers are exploring botanicals that have no connection to kratom, mitragynine, or 7-OH. These are separate plants with separate traditions of use, and they sit entirely outside the scheduling action discussed above — not because of a favorable reading of the threshold, but because the compounds at issue are not present in them at all.

Cat's Claw (Uncaria tomentosa) is one such botanical. It is a woody vine native to the Amazon basin, from the genus Uncaria in the coffee family, and it has a long history of traditional use in South America. It contains no mitragynine and no 7-hydroxymitragynine of any kind. The Cat's Claw products we carry contain no kratom, no mitragynine, and no 7-OH, are third-party lab tested with batch results published, and are formulated for adults 21+.

We want to be precise about what we are and are not saying. Cat's Claw is a different plant with a different composition, and we make no comparison whatsoever to the effects of kratom, 7-OH, or any other substance. Anyone telling you a botanical product substitutes for something else is telling you something we will not.

Cat's Claw products are legal in all 50 states.** Every batch we sell is third-party tested and the documentation is posted on our certificate of analysis page. If the botanical is new to you, what is Cat's Claw is the place to start, and the full Cat's Claw collection lists everything we currently carry.

** Legality depends on the specific formulation of a given product and on applicable state and local law, which can change. Customers should check the law in their own jurisdiction. Nothing on this page is legal advice.

Frequently Asked Questions

Will 7-OH tablets disappear from stores on August 5?

The order may publish on or after August 5, 2026 and takes effect on the date it publishes, so the exact date is not fixed in advance. In practice, retailers tend to clear affected inventory in the weeks leading up to an effective date rather than on it, so availability will thin out before any single day.

Are the brands named in this post doing something wrong?

This post makes no such claim. It compares published product specifications to a published regulatory threshold. How any company responds — reformulating, discontinuing, or otherwise — is that company's decision to make with its own counsel.

Does this affect ordinary kratom leaf products?

The action targets 7-OH above the specified threshold. Ordinary botanical leaf material containing only trace naturally-occurring 7-OH below 0.05% is not within its scope as filed. State law is a separate matter and varies.

Is Cat's Claw related to kratom?

No. They are different plants. Cat's Claw is Uncaria tomentosa, a vine native to the Amazon; kratom is Mitragyna speciosa, a tree native to Southeast Asia. Cat's Claw contains no mitragynine or 7-hydroxymitragynine.

How long will the temporary scheduling last?

Two years from the date the order takes effect, with the possibility of an extension while permanent scheduling is considered. The DEA's July 1 press release and the Federal Register notice (91 FR 40917, Docket No. DEA-1570) are the primary sources.

These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Consult a qualified healthcare professional before use.